Gilles Peytavin

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

Delphine Desbois, Bénédicte Roquebert, Gilles Peytavin et al. · Antimicrobial Agents and Chemotherapy · 2008 · 121 citations · Full text

Immunology, Antiviral Drug, Clinical Isolates +17

CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort

Sophie Matheron, Florence Damond, Antoine Bénard et al. · AIDS · 2006 · 52 citations

Mechanisms of Early Virologic Failure in Antiretroviral‐Naive Patients Starting Protease Inhibitor–Containing Regimens: The APROVIR Study

Bernard Masquelier, Gilles Peytavin, Catherine Leport et al. · The Journal of Infectious Diseases · 2002 · 24 citations

Virologic Failure, Pi Plasma Levels, Early Vf +15

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance

Bernard Masquelier, Edwige Pereira, Gilles Peytavin et al. · Journal of Clinical Virology · 2005 · 22 citations

Inhibitory Activity, Pharmacology, Intermittent Viremia +6

<i>In vitro</i> Phenotypic Susceptibility to Nucleoside Reverse Transcriptase Inhibitors of HIV-2 Isolates with the Q151M Mutation in the Reverse Transcriptase Gene

Florence Damond, Gilles Collin, Sophie Matheron et al. · Antiviral Therapy · 2005 · 21 citations · Full text